Emmaus Life Sciences Reports Annual Financial Results

Biopharmaceutical company sees 25% revenue decline in 2025 due to generic competition, but reduces operating expenses by 34%

Mar. 31, 2026 at 6:53am

Got story updates? Submit your updates here. ›

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported its financial results for the year ended December 31, 2025. The company experienced a 25% decline in net revenues in 2025 compared to 2024 due to ongoing competition from generic L-Glutamine in the U.S., partially offset by an increase in sales in the Middle East North Africa (MENA) region. However, Emmaus realized income from operations of $0.2 million compared to a loss of $1.9 million in the prior year, due to a 34% reduction in operating expenses.

Why it matters

Emmaus is a key player in the sickle cell disease treatment market, and its financial performance reflects the challenges of competing with generic drugs while also navigating growth opportunities in international markets. The company's shift in strategy for its U.S. operations could have significant implications for its future competitiveness.

The details

Emmaus reported net revenues of $12.5 million for 2025, down from $16.7 million in 2024, due to decreased U.S. sales from generic competition. However, the company was able to reduce total operating expenses by 34% to $11.4 million, leading to income from operations of $0.2 million compared to a loss of $1.9 million in the prior year. Other expenses, including loss on debt extinguishment and increased interest expense, resulted in a net loss of $7.2 million for 2025.

  • Emmaus reported financial results for the year ended December 31, 2025.
  • The company experienced a 25% decline in net revenues in 2025 compared to 2024.

The players

Emmaus Life Sciences, Inc.

A commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease.

Willis Lee

Chairman and Chief Executive Officer of Emmaus.

NeoImmuneTech, Inc.

A company with which Emmaus has entered into a license and exclusive distribution arrangement for its U.S. operations.

Got photos? Submit your photos here. ›

What they’re saying

“We experienced a 25% decline in net revenues in 2025 as compared to 2024 due to ongoing competition from generic L-Glutamine in the U.S., partially offset by an increase of sales in the Middle East North Africa, or MENA, region.”

— Willis Lee, Chairman and Chief Executive Officer

“We believe the international markets offer greater growth potential and have undertaken a change in strategy for our U.S. operations going forward by entering into a license and exclusive distribution arrangement with NeoImmuneTech, Inc. which we expect to be fully implemented in the second quarter of this year.”

— Willis Lee, Chairman and Chief Executive Officer

What’s next

Emmaus expects its new license and exclusive distribution arrangement with NeoImmuneTech, Inc. for its U.S. operations to be fully implemented in the second quarter of 2026.

The takeaway

Emmaus Life Sciences is navigating the challenges of generic competition in the U.S. sickle cell disease treatment market by shifting its focus to international growth opportunities, particularly in the MENA region, while also restructuring its U.S. operations through a new partnership. The company's ability to reduce operating expenses and maintain profitability will be crucial to its long-term success.